Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005654 · ClinicalTrials.gov registry record
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
A clinical trial of Neuroblastoma and Thyroid Neoplasms, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 2,415
- Enrollment target
- 1
- Study location
NCT01005654: Recruiting study of Neuroblastoma and Thyroid Neoplasms, sponsored by National Cancer Institute (NCI).
NCT01005654 is a study of Neuroblastoma and Thyroid Neoplasms that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 2,415 participants, above the 213-participant average among 94 other Neuroblastoma trials with a reported enrollment target (1034% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01005654, a study of Neuroblastoma and Thyroid Neoplasms, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 2,415 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to improve detection and treatment options for patients who develop these kinds of cancer. * Researchers are interested in studying the molecular changes that are involved in endocrine cancer development and growth. To collect a sample of tumor specimens and healthy tissue for further study, researchers are specifically looking for samples from participants who are scheduled for surgery or biopsy on endocrine tumors. Objectives: \- To collect samples of precancerous, cancerous, and healthy tissue from individuals who are scheduled for surgery or biopsy of endocrine system tumors. Eligibility: \- Individuals who have a tumor in or around their thyroid, parathyroid, adrenal gland, pancreas, or any neuroendocrine tissue, and are scheduled for surgery at the National Institutes of Health Clinical Center. Design: * Participants in this study will provide blood and urine samples prior to surgery. * During the surgery or biopsy, pieces of the tumor or precancerous growth and pieces of normal tissue near to the tumor will be removed for ongoing and future research. The rest of the tumor or growth will be sent for analysis. * After surgery, participants will receive routine care until discharge, and doctors will discuss possible treatment options. If there is an appropriate NIH protocol, participants may choose to be treated at the NIH. * After discharge, participants will return to the clinic for a routine postoperative check about 6 weeks following the operation, and then may be followed yearly at the Clinical Center or by phone....
Primary Outcome
To develop a genetic, epigenetic, metabolomic, and proteomic profile of endocrine neoplasm that will allow us to distinguish benign from malignant tumor for each of the endocrine histologies under study.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,415 participants |
| Start Date | 2009-10-07 |
What NCT01005654 shows while recruiting
NCT01005654 is an observational study that tracks outcomes without assigning an intervention. Its 2,415 participants enrollment target places it among the larger protocols in the corpus, above the 213-participant average among 94 other Neuroblastoma trials with a reported enrollment target (1034% higher).
The record links to 5 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT01005654 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01005654 about?
NCT01005654 is a clinical study titled "Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms". Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to imp...
What is the current status of trial NCT01005654?
This trial is currently recruiting. The enrollment target is 2,415 participants. The study started on 2009-10-07.
What conditions does trial NCT01005654 study?
This clinical trial studies the following conditions: Neuroblastoma, Thyroid Neoplasms, Endocrine Tumors, Parathyroid Neoplasms, Adrenal Neoplasm.
Who is sponsoring clinical trial NCT01005654?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01005654 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01005654's enrollment target sits among peer trials
2,415 2nd of 94 the highest of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Neuroblastoma Biology Study
RECRUITING
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05873387 · 2,420 participants
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
- NCT05345951 · 2,425 participants · NA
Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI